EP1735279A1

EP1735279A1 - Prolinyl derivates for treating thrombosis

Info

Publication number: EP1735279A1
Application number: EP05715737A
Authority: EP
Inventors: Werner Mederski; Christos Tsaklakidis; Dieter Dorsch; Bertram Cezanne; Johannes Gleitz
Original assignee: Merck Patent GmbH
Current assignee: Merck Patent GmbH
Priority date: 2004-03-26
Filing date: 2005-03-04
Publication date: 2006-12-27
Also published as: AU2005225489A1; DE102004014945A1; MXPA06010771A; CN1938269A; RU2006137656A; US20070135507A1; JP2007530469A; KR20070010131A; US7683093B2; WO2005092849A1; AR048326A1; AU2005225489B2; ZA200608875B; BRPI0509174A; CA2561057A1

Abstract

The invention relates to novel compounds of formula (I), in which R, R<1>, R<2>, R<3> and R<4> are defined as cited in claim 1. Said compounds are inhibitors of the coagulation factor Xa and can be used for the prophylaxis and/or treatment of thromboembolic diseases and for the treatment of tumours.

Description

PROLINYL DERIVATIVES FOR TREATING THROMBOSE

The invention relates to compounds of the formula

wherein R shark, -C - CH, -C≡CA or OA, r->. H, = 0, shark, A, OH, OA, A-COO-, Ph- (CH ₂ ) _n -COO-, cycloalkyl- (CH ₂ ) _n -COO-, A-CONH-, A-CONA-, Ph-CONA-, N ₃ , NH ₂ , N0 ₂ , CN, COOH, COOA, CONH ₂ , CONHA, CON (A) ₂ , O-allyl, O-propargyl, O-benzyl, = N-OH, = N -OA or = CF ₂ ,

R ^ H or A, Ph unsubstituted or phenyl substituted once, twice or three times by A, OA, OH or shark,

R ^J H, shark or A,

R ⁴ -C ₆ H ₄ - (CH ₂ ) n-NR ⁵ R ^{5 '} , -C (= NR ⁵ ) NR ⁴ R ^5' ₎

R ⁵ , R ^{5 '} each independently of one another are H or A, unbranched, branched or cyclic alkyl having 1-12 C atoms, in which 1-7 H atoms can also be replaced by F and / or chlorine,

Hai F. CI, Br or l, n 0, 1, 2 or 3, mean, and their pharmaceutically usable derivatives, solvates, salts and

Stereoisomers, including their mixtures in all proportions.

The object of the invention was to find new compounds with valuable properties, in particular those which can be used for the production of medicaments.

It has been found that the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability. In particular, they show factor Xa inhibitory properties and can therefore be used to combat and prevent thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis,

Inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication can be used.

The compounds of the formula I according to the invention can furthermore be inhibitors of the coagulation factors factor VIIa, factor IXa and thrombin of the blood coagulation cascade.

Aromatic amidine derivatives with antithrombotic activity are e.g. from EP 0 540 051 B1, WO 98/28269, WO 00/71508, WO 00/71511, WO 00/71493, WO 00/71507, WO 00/71509, WO 00/71512, WO 00/71515 or WO 00 / 71516 known. Cyclic guanidines for the treatment of thromboembolic diseases are e.g. described in WO 97/08165. Aromatic heterocycles with factor Xa inhibitory activity are e.g. known from WO 96/10022. Substituted N - [(aminoiminomethyl) phenylalkylj-azaheterocyclylamides as factor Xa inhibitors are described in WO 96/40679.

Other carboxamide derivatives are known from WO 02/48099 and WO 02/57236, other pyrrolidine derivatives are described in WO 02/100830. Further heterocyclic derivatives are known from WO 03/045912.

Pyrrolidine derivatives as inhibitors of the endothelin converting enzyme are known from WO 02/06222.

Pyrrolidine derivatives as cholecystokinin and gastrin inhibitors are in the

US 5,340,801. Other pyrrolidine derivatives are known from WO

01/044192.

The antithrombotic and anticoagulant effect of the compounds according to the invention is attributed to the inhibitory effect on the activated coagulation protease, known under the name factor Xa, or to the inhibition of other activated serine proteases such as factor VI la, factor IXa or thrombin.

Factor Xa is one of the proteases involved in the complex process of

Blood clotting is involved. Factor Xa catalyzes the conversion of

Prothrombin in thrombin. Thrombin cleaves fibrinogen into fibrin monomers which, after cross-linking, make an elementary contribution to thrombus formation. A

Activation of thrombin can lead to the occurrence of thromboembolic

Lead diseases. An inhibition of thrombin can, however, in the

Inhibit fibrin formation involved in thrombus formation.

The measurement of the inhibition of thrombin can e.g. using the method of G.F. Cousins et al. in Circulation 1996, 94, 1705-1712.

Inhibition of factor Xa can thus prevent thrombin from being formed. The compounds of formula I according to the invention and their salts interfere with the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.

The inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulant and anti- Thrombotic activity can be determined by conventional in vitro or in vivo methods. A suitable method is described, for example, by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223. 5

The measurement of the inhibition of factor Xa can e.g. using the method of T. Hara et al. in thromb. Haemostas. 1994, 71, 314-319.

10 The coagulation factor Vlla initiates the extrinsic part of the coagulation cascade after binding to tissue factor and contributes to the activation of factor X to factor Xa. Inhibition of factor VIIa thus prevents the development of factor Xa and thus a subsequent one

-J5 thrombin formation. The inhibition of the factor VIIa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods. A common method for measuring factor VIIIa inhibition is e.g. by H. F. Ronning et al. in Thrombosis Research 1996, 84, 73-81.

The coagulation factor IXa is generated in the intrinsic coagulation cascade 5 and is also involved in the activation of factor X to factor Xa. Inhibition of factor IXa can therefore otherwise prevent factor Xa from being formed. The inhibition of factor IXa by the Q compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods. A suitable method is described, for example, by J. Chang et al. in Journal of Biological Chemistry 1998, 273, 12089-12094. 5 The compounds according to the invention can furthermore be used for the treatment of tumors, tumor diseases and / or tumor metastases.

A relationship between the tissue factor TF / factor Vlla and the

Development of various types of cancer was by T.Taniguchi and

N.R. Lemoine in Biomed. Health Res. (2000), 41 (Molecular Pathogenesis of Pancreatic Cancer), 57-59.

The publications listed below describe an anti-tumor effect of TF-VII and factor Xa inhibitors in various

Tumor types:

K. M. Donnelly et al. in thromb. Haemost. 1998; 79: 1041-1047;

E.G. Fischer et al. in J. Clin. Invest. 104: 1213-1221 (1999); B. M. Mueller et al. in J. Clin. Invest. 101: 1372-1378 (1998);

M. E. Bromberg et al. in thromb. Haemost. 1999; 82: 88-92

The compounds of formula i can be used as active pharmaceutical ingredients in human and veterinary medicine, in particular for the treatment and prevention of thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, venous thrombosis, pulmonary embolism, arterial thrombosis, myocardial ischaemia, unstable angina and thrombosis-based stroke.

The compounds according to the invention are also used for the treatment or prophylaxis of atherosclerotic diseases such as coronary arterial disease, cerebral arterial disease or peripheral arterial disease.

The compounds are also used in combination with other thrombolytics for myocardial infarction, as well as for prophylaxis for reocclusion after thrombolysis, percutaneous transluminal angioplasty (PTCA) and coronary bypass surgery. The compounds according to the invention are also used for the prevention of rethrombosis in microsurgery, also as anticoagulants in connection with artificial organs or in hemodialysis. The compounds are also used in the cleaning of catheters and medical devices in patients in vivo, or as anticoagulants for the preservation of blood, plasma and other blood products in vitro. The compounds according to the invention are also used in diseases in which blood coagulation makes a decisive contribution to the course of the disease or is a source of secondary pathology, such as, for example, cancer including metastasis, inflammatory diseases including arthritis, and diabetes.

The compounds according to the invention are also used to treat migraines (F. Morales-Asin et al., Headache, 40, 2000, 45-47) .0 In addition, they can be used to treat tinnitus. The use of anticoagulants in tinnitus therapy has been described by R. Mora et al. in International Tinnitus Journal (2003), 9 (2), 109-111.5 In the treatment of the diseases described, the compounds according to the invention are also used in combination with other thrombolytically active compounds, for example with the "tissue plasminogen activator" t PA, modified t-PA, streptokinase or urokinase. The compounds according to the invention are administered with the other substances mentioned either simultaneously or before or after. Co-administration with aspirin is particularly preferred in order to prevent recurrence of thrombus formation. The compounds according to the invention are also used in combination with platelet glycoprotein receptor (llb / llla) antagonists which inhibit platelet aggregation.

The invention relates to the compounds of formula I and their

Salts and a process for the preparation of compounds of formula I according to claims 1-16 and their pharmaceutically usable

Derivatives, solvates, salts and stereoisomers, characterized in that a) a compound of formula II

wherein R has the meaning given in claim 1,

with a chloroformate derivative to form an intermediate carbamate derivative, which is then reacted with a compound of formula III

R ³ wherein

R ¹ , R ² , R ³ and R ^{4 have} the meaning given in claim 1,

is implemented

or b) a compound of formula III

with a compound of formula IV

wherein

R has the meaning given in claim 1,

implements,

or

c) a compound of formula V

wherein R ³ and R ^{4 have} the meaning given in claim 1,

with a compound of formula VI

wherein L is Cl, Br, I or a free or reactive functional OH group and R, R ¹ and R ^{2 have} the meanings given in Claim 1, 5, and / or 10 a base or acid of the formula I in one of their salts.

The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates and the diastereomers

A ₅ and the hydrates and solvates of these compounds. Solvates of the compounds are understood to mean the addition of inert solvent molecules to the compounds, which are formed on account of their mutual attraction. Solvates are, for example, mono- or dihydrates or alcoholates. 0

Pharmaceutically usable derivatives are e.g. the salts of the compounds according to the invention and also so-called prodrug compounds. 5 Prodrug derivatives are understood with z. B. alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which are quickly cleaved in the organism to the active compounds of the invention. Q This also includes biodegradable polymer derivatives of the compounds according to the invention, as z. B. in Int. J. Pharm. 115. 61-67 (1995).

The invention also relates to mixtures of the invention

35 compounds of the formula I, for example mixtures of two diastereomers, for example in the ratio 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 100 or 1: 1000. These are particularly preferably mixtures of stereoisomeric compounds.

For all residues that occur several times, e.g. A, the meanings are independent of each other.

Above and below, the radicals or parameters R, R ¹ , R ² , R ³ , R ^{4 have} the meanings given in the formula I, unless expressly stated otherwise.

A means alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2 , 2-

Dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3- Dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, more preferably for example Trifluoromethyl. A also means cycloalkyl. Cycloalkyl preferably means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

A therefore also preferably denotes cyclopentylmethyl, cyclohexylmethyl, A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1, 1, 1-trifluoroethyl.

R is preferably shark or -C≡C-H.

R ¹ is preferably H, = 0 (carbonyl oxygen), shark, A, OH or OA, particularly preferably OH or OA.

R ² is preferably H.

R ³ is preferably H or shark. R ⁴ is preferably -C ₆ H ₄ -CH ₂ -N (CH ₃ ) ₂ , -C (= NH) N (CH ₃ ) ₂ ,

R ⁵ , R ⁵ each preferably independently of one another denote H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.

The compounds of formula I can have one or more chiral centers and therefore exist in various stereoisomeric forms. Formula I encompasses all of these forms.

Accordingly, the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above. Some preferred groups of compounds can be expressed by the following sub-formulas Ia to Ig, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which

in la R represents shark or -C- -H;

in lb R ^{1 is} H, = 0, shark, A, OH or OA;

in Ic R ^{1 is} OH or OA;

in Id R ³ denotes H or shark; in le R ⁵ , R ⁵ each independently represent H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;

in If R ³ denotes H or alkyl having, 2, 3, 4, 5 or 6 carbon atoms;

in Ig R shark or -C≡CH, R ¹ OH or OA R ² H or A, R ³ H or shark, R ⁴ -C ₆ H ₄ - (CH ₂ ) _n -NR ⁵ R ⁵ ,, -C ( = NR ⁵ ) NR ⁴ R ^{5 '} ,

R ⁵ , R ⁵ each independently of one another H or A, A unbranched, branched or cyclic alkyl having 1-12 C atoms, in which 1-7 H atoms can also be replaced by F and / or chlorine, Hai F, Cl , Br or I, n represent 0, 1, 2 or 3;

as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios.

The compounds of the formula I and also the starting materials for their preparation are otherwise prepared by methods known per se, as described in the literature (e.g. in the standard works such as Houben-Weyl,

Methods of organic chemistry, Georg-Thieme-Verlag, Stuttgart) are described, namely under reaction conditions which are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in detail.

If desired, the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.

Compounds of formula I can preferably be obtained by treating compounds of formula II with a chloroformate derivative, e.g. 4-nitrophenyl chloroformate is converted to an intermediate carbamate and then reacted with compounds of the formula IM.

The reaction is usually carried out in an inert solvent, in the presence of an acid-binding agent, preferably an alkali metal or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali metal or alkaline earth metal, preferably potassium, sodium, calcium or cesium. Also the

Addition of an organic base such as triethylamine, dimethylaniline, pyridine or quinoline can be beneficial. Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0 ° and 150 °, usually between

20 ° and 130 °.

Suitable inert solvents are e.g. Water; Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran

(THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (Diglyme); Ketones such as acetone or butanone; Amides such as acetamide,

Dimethylacetamide or dimethylformamide (DMF); Nitriles such as acetonitrile;

Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide;

Carboxylic acids such as formic acid or acetic acid; Nitro compounds like

Nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of the solvents mentioned.

The starting compounds of the formulas II and III are generally known. If they are new, they can be manufactured according to methods known per se.

Compounds of formula I can also be obtained by reacting compounds of formula III with compounds of formula IV.

This is done under conditions as described above.

The starting compounds of the formula IV are generally known. If they are new, they can be manufactured according to methods known per se.

Compounds of the formula I can also be obtained by reacting compounds of the formula V with compounds of the formula VI. In the compounds of formula VI, L is preferably Cl, Br, I or a reactively modified OH group such as e.g. an activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy with 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).

Such residues for activating the carboxy group in typical acylation reactions are described in the literature (e.g. in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg-Thieme-Verlag, Stuttgart;).

Activated esters are conveniently formed in situ, e.g. B. by adding HOBt or N-hydroxysuccinimide. The reaction is usually carried out in an inert solvent

Presence of an acid-binding agent, preferably an alkali or

Alkaline earth metal hydroxides, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals, preferably potassium, sodium, calcium or cesium. Also the

Addition of an organic base such as triethylamine, dimethylaniline, pyridine or quinoline or an excess of the amine component of the formula IV can be advantageous. Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0 ° and 150 °, normally between 20 ° and 130 °. Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of the solvents mentioned.

Esters can be saponified, for example, with acetic acid or with NaOH or KOH in water, water-THF or water-dioxane at temperatures between 0 and 100 °. Pharmaceutical salts and other forms The compounds according to the invention mentioned can be used in their final non-salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by methods known in the art. Pharmaceutically acceptable

Most of the salt forms of the compounds of the formula I are prepared conventionally. If the compound of formula I contains a carboxylic acid group, one of its suitable salts can be formed by reacting the compound with a suitable base

Λ _C base addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide; Alkali metal alcoholates, for example potassium ethanolate and sodium propanolate; as well as various organic bases such as piperidine, diethanolamine and 0 N-methylglutamine. The aluminum salts of the compounds of formula I also count. For certain compounds of the formula I, acid addition salts can be formed by reacting these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like and alkyl - And monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate, Q and other organic acids and their corresponding salts such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like are treated. Accordingly, pharmaceutically acceptable acid addition salts of the compounds of the formula I include the following: acetate, adipate, alginate, arginate, aspartate, 5 benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphor sulfonate, caprylate, chloride, chlorobenzoate citrate, Cyclopentane propionate, digluconate, dihydrogen phosphate, dinitrobenzoate,

Dodecyl sulfate, ethanesulfonate, fumarate, galactate (from mucic acid),

Galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate,

Hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride,

Hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate,

Isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate,

Metaphosphate, methanesulfonate, methyl benzoate, monohydrogen phosphate,

2-naphthalene sulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate,

Phthalate, but this is not a limitation.

The base salts of the compounds according to the invention also include aluminum, ammonium, calcium, copper, iron (III), iron (II), lithium, magnesium, manganese (III), manganese (II), potassium -, sodium and zinc salts, but this should not be a limitation. Preferred among the salts mentioned above are ammonium; the

Alkali metal salts sodium and potassium, as well as the alkaline earth metal salts

Calcium and magnesium. To salts of the compounds of formula I, which differ from pharmaceutically acceptable organic non-toxic

Deriving bases include salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g.

Arginine, betaine, caffeine, chlorprocaine, choline, N, N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine Glucosamine, histidine,

Hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procain, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris (hydroxymethyl) methylamine ( Tromethamine), but this should not be a limitation. Compounds of the present invention which are basic nitrogenous

Contain groups can be with agents such as (CC ₄ ) alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide;

Di (CC ₄ ) alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C ₁₀ -

C ₁₈ ) alkyl halides, for example decyl, dodecyl, lauryl, myristyl and

Stearyl chloride, bromide and iodide; and aryl (-C ₄ ) alkyl halides, for example

Benzyl chloride and phenethyl bromide, quartemize. Such salts can be used to prepare both water-soluble and oil-soluble compounds according to the invention.

The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, Sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to be a limitation.

The acid addition salts of basic compounds of formula I are prepared in that the free base form with a sufficient

The amount of the desired acid is brought into contact, which leads to the usual

Way the salt represents. The free base can be obtained by contacting the salt form with a base and isolating the free base to conventional ones

Regenerate wisely. The free base forms differ in a sense from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; in the context of the invention, however, the salts otherwise correspond to their respective free base forms.

As mentioned, the pharmaceutically acceptable base addition salts of the compounds of the formula I are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines.

Preferred metals are sodium, potassium, magnesium and calcium. Before- Preferred organic amines are N.N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

The base addition salts of acidic compounds according to the invention are prepared by contacting the free acid form with a sufficient amount of the desired base, whereby the salt is prepared in the usual way. The free acid can pass through

Regenerate the salt form with an acid and isolate the free acid in the usual manner. The free acid forms differ in a sense from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; in the context of the invention, however, the salts otherwise correspond to their respective free acid forms.

If a compound according to the invention contains more than one group which can form such pharmaceutically acceptable salts, the invention also includes multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to be a limitation.

In view of the above, it can be seen that the term "pharmaceutically acceptable salt" in the present context is to be understood as meaning an active ingredient which contains a compound of the formula I in the form of one of its salts, in particular when this salt form contains the active ingredient Gives improved pharmacokinetic properties when compared to the free form of the active ingredient or any other salt form of the active ingredient used previously. The pharmaceutically acceptable salt form of the active ingredient can only give this active ingredient a desired pharmacokinetic property that it did not previously have, and can even improve pharmacodynamics positively influence this active ingredient in terms of its therapeutic effectiveness in the body.

Compounds of the formula I according to the invention can be chiral due to their molecular structure and can accordingly occur in various enantiomeric forms. They can therefore be in racemic or optically active form.

Since the pharmaceutical activity of the racemates or the stereoisomers of the compounds according to the invention can differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art, or can already be used as such in the synthesis.

In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active release agent. Suitable release agents are e.g. optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (e.g. N-benzoylproline or N-benzenesulfonylproline) or the various optically active camphorsulfonic acids. Chromatographic separation of enantiomers using an optically active separating agent (e.g. dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chiral derivatized methacrylate polymers fixed on silica gel) is also advantageous. Aqueous or alcoholic solvent mixtures such as e.g. Hexane / isopropanol / acetonitrile e.g. in the ratio 82: 15: 3.

The invention further relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the production of a medicament (pharmaceutical preparation), in particular in a non-chemical way. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients. 5

The invention further relates to medicaments containing at least one compound of the formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and, if appropriate, carriers and / or auxiliaries.

Pharmaceutical formulations can be presented in the form of dose units containing a predetermined amount of active ingredient per dose unit.

_ _| {- be enough. Such a unit can contain, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition of the disease treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dose units which contain a predetermined amount of active ingredient per dose unit. Preferred dosage unit formulations are those which contain a daily dose or partial dose, as stated above, or a corresponding fraction thereof of an active ingredient. Furthermore, such pharmaceutical formulations can be produced using one of the methods generally known in the pharmaceutical field. Pharmaceutical formulations can be administered for administration by any suitable route, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramus)

35 pathways, intravenous or intradermal). Such formulations can be used with anyone in the pharmaceutical field known processes can be produced, for example, by bringing the active ingredient together with the carrier (s) or auxiliary (s).

5 Pharmaceutical formulations adapted for oral administration can be administered as separate units, e.g. Capsules or tablets; Powder or granules; Solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam dishes; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

For example, in the case of oral administration in the form of a _. _c tablet or capsule combine the active ingredient with an oral, non-toxic and pharmaceutically acceptable inert carrier, such as ethanol, glycerin, water and others. Powders are made by crushing the compound to an appropriate fine size and mixing it with a similarly crushed pharmaceutical carrier such as an edible carbohydrate such as starch or mannitol. A flavor, preservative, dispersant and color may also be present. 5 capsules are made by making a powder mixture as described above and filling shaped gelatin shells with it. Lubricants and lubricants such as highly disperse silica, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form Q can be added to the powder mixture before the filling process. A disintegrant or solubilizer, such as agar, calcium carbonate or sodium carbonate, can also be added to improve the availability of the medication after taking the capsule. 5 In addition, if desired or necessary, suitable binding agents, lubricants and disintegrants as well as dyes can also be added to the mixture be incorporated. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, sweeteners from corn, natural and synthetic gums such as acacia,

Tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol,

Waxes, etc. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and others. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and others. The tablets are formulated by, for example, producing a powder mixture, granulating or pressing them dry, adding a lubricant and a disintegrant and compressing the whole thing into tablets. A powder mixture is prepared by appropriately comminuting the compound with a diluent or a base as described above and optionally with a binder such as e.g. Carboxymethylcellulose, an alginate, gelatin or polyvinylpyrrolidone, a solution slower, e.g. Paraffin, a resorption accelerator, e.g. a quaternary salt and / or an absorbent such as e.g. Bentonite, kaolin or dicalcium phosphate is mixed. The powder mixture can be granulated by mixing it with a binder such as e.g. Syrup, starch paste, Acadia slime or solutions made of cellulose or polymer materials are wetted and pressed through a sieve. As an alternative to

The powder mixture can be granulated through a tabletting machine, with irregularly shaped lumps which are broken up into granules. The granules can be greased by adding stearic acid, a stearate salt, talc or mineral oil to prevent sticking to the tablet molds. The greased mixture is then compressed into tablets. The compounds according to the invention can also be combined with a free-flowing inert carrier and then pressed directly into tablets without carrying out the granulation or dry compression steps. A transparent or opaque protective layer consisting of A shellac sealant, a layer of sugar or polymeric material, and a glossy layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.

Oral liquids, e.g. Solution, syrups and elixirs can be prepared in unit dosage forms so that a given quantity contains a given amount of the compound. Syrups can be made by dissolving the compound in an aqueous solution with a suitable taste, while elixirs are made using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers, e.g. ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers,

Preservatives, flavor additives, e.g. Peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, etc. can also be added.

Dosage unit formulations for oral administration can optionally be enclosed in microcapsules. The formulation can also be prepared in such a way that the release is prolonged or delayed, for example by coating or embedding particulate material in polymers, wax and the like.

The compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be in the form of liposome delivery systems, such as e.g. administer small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.

Liposomes can be made from various phospholipids, e.g.

Cholesterol, stearylamine or phosphatidylcholines. The compounds of the formula I and the salts, solvates and physiologically functional derivatives thereof can also be supplied using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled with soluble polymers as targeted drug carriers.

Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl methacrylamide phenol, polyhydroxyethylaspartamide phenol or polyethylene oxide polylysine substituted with palmitoyl residues. Furthermore, the compounds can be linked to a class of biodegradable polymers suitable for achieving controlled release of a drug, e.g. Polylactic acid, polyepsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxy-pyrans, polycyanoacrylates and cross-linked or amphipatic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration can be administered as independent patches for prolonged, close contact with the epidermis of the recipient. For example, the active ingredient can be supplied from the patch by means of iontophoresis, as generally described in Pharmaceutical Research, 3 (6), 318 (1986).

Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

For treatments of the eye or other external tissues, such as the mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated into an ointment, the active ingredient can be used either with a paraffinic or with a water-miscible cream base. Alternatively, the active ingredient can be a Cream can be formulated with an oil-in-water cream base or a water-in-oil base.

Pharmaceutical formulations adapted for topical application to the eye include eye drops, the active ingredient being dissolved or suspended in a suitable carrier, in particular an aqueous solvent.

Pharmaceutical adapted to the topical application in the mouth

Formulations include lozenges, lozenges and mouthwashes.

Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.

Pharmaceutical formulations adapted for nasal administration, in which the carrier substance is a solid, contain a coarse powder with a particle size, for example in the range of 20-500 micrometers, which is administered in the manner in which snuff is taken up, i.e. by rapid inhalation via the nasal passages from a container with the powder held close to the nose. Suitable formulations for administration as a nasal spray or nasal drops with a liquid as carrier include active ingredient solutions in water or oil.

Pharmaceutical formulations adapted for administration by inhalation include fine particulate dusts or mists which can be generated by means of various types of pressurized metering dispensers with aerosols, nebulizers or insufflators. Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

For pharmaceuticals adapted for parenteral administration

Formulations include aqueous and non-aqueous sterile solutions for injection containing antioxidants, buffers, bacteriostatics and solutes by which the formulation is rendered isotonic with the blood of the recipient to be treated; as well as aqueous and non-aqueous sterile suspensions, which can contain suspending agents and thickeners. The formulations can be in single dose or multiple dose containers, e.g. sealed ampoules and vials, presented and stored in the freeze-dried (lyophilized) state so that only the addition of the sterile carrier liquid, e.g. Water for

Injection is required immediately before use.

Injection solutions and suspensions prepared according to the recipe can be made from sterile powders, granules and tablets.

It is understood that the formulations may contain, in addition to the above-mentioned ingredients, other means common in the art with respect to the particular type of formulation; for example, formulations suitable for oral administration may contain flavorings.

A therapeutically effective amount of a compound of Formula I depends on a number of factors, including e.g. the age and

Weight of the animal, the exact disease state that requires treatment, its severity, the nature of the formulation and the route of administration, and is ultimately determined by the treating doctor or veterinarian. However, an effective amount of a compound of the invention is generally in the range of 0.1 to 100 mg / kg body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg / kg body weight per day.

Thus, for a 70 kg adult mammal, the real one would be

Amount per day is usually between 70 and 700 mg, taking this

Quantity as a single dose per day or more usually in a series of partial doses

(such as two, three, four, five or six) per day so that the total daily dose is the same. An effective amount of one

Salt or solvate or a physiologically functional derivative thereof can be determined perse as a proportion of the effective amount of the compound according to the invention.

The compounds of the formula I and their physiologically acceptable salts can be used to combat and prevent thrombo-embolic diseases such as thrombosis, myocardial infarction,

Arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, migraine, tinnitus, tumors, tumor diseases and / or tumor metastases can be used.

The invention further relates to medicaments containing at least one compound of the formula I and / or their pharmaceutically usable

Derivatives, solvates, salts and stereoisomers, including their

Mixtures in all proportions, and at least one other drug ingredient.

The invention also relates to a set (kit) consisting of separate

Packs of (a) an effective amount of a compound of Formula I and / or its pharmaceutically acceptable derivatives, solvates, salts and stereoisomers, including their mixtures in all proportions, and

(b) an effective amount of another drug ingredient. The set contains suitable containers, such as boxes or cartons, individual bottles, bags or ampoules. The set can, for example, be separate

Contain ampoules, each containing an effective amount of one

Compound of formula I and / or their pharmaceutically usable

Derivatives, solvates, salts and stereoisomers, including their

Mixtures in all proportions, and an effective amount of another drug active dissolved or in lyophilized form.

The invention further relates to the use of compounds of the formula I and / or their pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all ratios, for the manufacture of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy , Angina pectoris, restenosis after angioplasty, intermittent claudication, migraine, tinnitus, tumors, tumor diseases and / or tumor metastases, in combination with at least one other active pharmaceutical ingredient.

All temperatures above and below are given in ° C. In the examples below, "customary work-up" means: if necessary, water is added, and if necessary, depending on the constitution of the end product, the pH is adjusted to between 2 and 10, extracted with ethyl acetate or dichloromethane, and the mixture is dried and dried organic phase over sodium sulfate, evaporates and purifies by chromatography on silica gel and / or by crystallization. Rf values on silica gel; Mobile solvent: ethyl acetate / methanol 9: 1.

Mass Spectrometry (MS): El (Electron Impact Ionization) M ⁺ ESI (Electrospray lonization) (M + H) ⁺ (unless otherwise stated) example 1

(2R, 4R) -4-Hydroxy-pyrrolidine-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - {[4- (2- {dimethylaminomethyl} phenyl) phenyl] -amid} ("A1")

The production is carried out according to the following scheme

1. 4 mmol of BOC-4-hydroxy-proline 1 as a suspension in 15 ml of toluene are stirred at room temperature in succession with 4 mmol of 2'-dimethylaminomethyl-biphenyl-4-ylamine 2 and 4 mmol of ethyl-2-ethoxy-1, 2 - added dihydroquinoline-1-carboxylate. Then this one

Temperature stirred 18 h. The mixture is then worked up in the customary manner and BOC-prolin-biphenylamine derivative 3 is thus obtained as the crude product.

2. 3 mmol of 3 are dissolved in 20 ml of dioxane and 20 ml of 4N HCl in doxane are added at room temperature and the mixture is stirred at this temperature for 2 h. The mixture is then worked up as usual and the proline biphenylamine derivative hydrochloride 4 is thus obtained as a crude product.

3. 1 mmol of 4-nitrophenyl chloroformate 5, 1 mmol of 4-chloroaniline and 1 mmol of pyridine in 10 ml of dichloromethane are stirred under a nitrogen atmosphere at room temperature for 1 h. Then 1 mmol of 4 and 3 mmol of N-ethyldiisopropylamine in 5mL dichloromethane are added. The resulting suspension is stirred for a further 2 h at room temperature. Then work up as usual and you get "A1".

The following compounds (2R, 4R) -4-hydroxy-pyrrolidin-1,2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2 - {[4- (2- {dimethylaminomethyl} -phenyl) -phenyl] -amide}, (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - {[2-fluoro- 4- (2- {dimethylaminomethyl} phenyl) phenyl] amide}, (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] - 2 - {[2-fluoro-4- (2- {dimethylaminomethyl} phenyl) phenyl] amide}, (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4- chlorophenyl) amide] -2 - [(4- (2-dimethylaminomethylimidazol-1-yl) phenyl) amide]

(2R, 4R) -4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2 - [(4- (2-dimethylaminomethylimidazol-1-yl) - phenyl) amide], (2R, 4R) -4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(2-fluoro-4- (2 -dimethylaminomethyl-imidazol-1-yl) -phenyl) -amide], (2R, 4R) -4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2- [(2-fluoro-4- (2-dimethylaminomethyl-imidazol-1-yl) -phenyl) -amide].

Example 2

The preparation of the intermediate (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(4-cyanophenyl) amide] ( "7") is carried out analogously to Example 1 and as shown in the diagram below.

Example 3

Preparation of the intermediate (2R, 4R) -4-hydroxy-pyrrolidin-1,2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(4-methoxycarbonimidoylphenyl) amide] (" 8th")

Compound "7" is dissolved in dry methanol. At 0 ° the solution is saturated with HCI gas. The mixture is stirred at room temperature for 12 h and, after customary working up, "8" is obtained.

Example 4

(2R, 4R) -4-Hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(4- (Λ /, Λ / -dimethyl-amidino) - phenyl) amide] ("A4")

Compound "8" is dissolved in dry methanol. 5 equivalents of dimethylamine (2M in methanol) are added and the mixture is heated under reflux. After 1 hour you work up as usual and get "A4".

The following compounds are obtained analogously (2R, 4R) -4-Hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2 - [(4- (A /, Λ / -dimethyl-amidino) - phenyl) amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(2-fluoro-4- (Λ /, Λ / -dimethyl-amidino) -phenyl) -amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2- [(2-fluoro-4- (Λ /, Λ / -dimethyl-amidino) -phenyl) -amide].

Example 5

(2R, 4R) -4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(4- (1-methyl-4,5-dihydro-1 H-imidazol-2-yl) phenyl) amide] ("A5")

Compound "8" is dissolved in dry methanol. 3 equivalents of N-methyl-ethane-1,1-diamine are added and the mixture is heated under reflux. After 1 hour you work up as usual and get "A5".

The following compounds are obtained analogously

(2R, 4R) -4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(2-fluoro-4- (1-methyl-4,5 -dihydro-1 H-imidazol-2-yl) -phenyl) -amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2 - [(4- (1-methyl-4,5-dihydro-1H-imidazol-2-yl) phenyl) amide], (2R, 4R) -4-hydroxy-pyrrolidin-1,2-dicarboxylic acid -1 - [(4-ethynylphenyl) amide] -2 - [(2-fluoro-4- (1-methyl-4,5-dihydro-1 H -imidazol-2-yl) phenyl) amide ]. The following examples relate to pharmaceutical preparations:

Example A: Injection glasses

A solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection glass contains 5 mg of active ingredient.

Example B: Suppositories

A mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.

Example C: solution

A solution of 1 g of an active ingredient is prepared of the formula I, 9.38 g of NaH ₂ P0 ₄ • 2 H ₂ 0, 28.48 g Na ₂ HP0 ₄ • 12 H ₂ 0 and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.

Example D: ointment

500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.

Example E: tablets

A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient. Example F: coated tablets

Analogously to Example E, tablets are pressed, which are then made in the usual manner

To be coated with a coating of sucrose, potato starch, talc, tragacanth and color.

Example G: capsules

2 kg of active ingredient of the formula I are filled into hard gelatin capsules in a conventional manner, so that each capsule contains 20 mg of the active ingredient.

Example H: ampoules

A solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.

Claims

claims

Compounds of formula I.

wherein

R shark, -C - C-H, -C --C-A or OA,

R ¹ H, = 0, shark, A, OH, OA, A-COO-, Ph- (CH ₂ ) _n -COO-, cycloalkyl- (CH ₂ ) _n -COO-, A-CONH-, A-CONA -, Ph-CONA-, N ₃ , NH ₂ , N0 ₂ , CN, COOH, COOA, CONH ₂ , CONHA, CON (A) ₂ , O-allyl, O-propargyl, O-benzyl, = N-OH, = N-OA or = CF ₂ ,

R ^J H, shark or A,

R ^5, R ^{5 'are} each independently H or A, straight, branched or cyclic alkyl having 1 ^■ 12 C atoms, in which 1-7 H atoms are replaced by F and / or chlorine may be replaced,

Shark F, Cl, Br or I, n 0, 1, 2 or 3, mean, and their pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all proportions.

2. Compounds according to claim 1, wherein R is shark or -C ≡C-H, and their pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all proportions.

3. Compounds according to claim 1 or 2, wherein R ¹ H, = 0, Hal. A, OH or OA means, and their pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all proportions.

4. Compounds according to one or more of claims 1-3, wherein R ^{1 is} OH or OA, and their pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all ratios.

Compounds according to one or more of claims 1-4, wherein R ^{3 is} H or shark, and their pharmaceutically usable derivatives, solvates, salts and stereoisomers, including mixtures thereof in all ratios.

6. Compounds according to one or more of claims 1-5, wherein R ⁵ , R ⁵ each independently represent H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, and their pharmaceutically usable derivatives, solvates, Salts and stereoisomers, including their mixtures in all proportions.

7. Compounds according to claim 1, wherein R shark or -C - CH, R ¹ OH or OA R ² H or A, R ³ H or shark, R ⁴ -C ₆ H ₄ - (CH ₂ ) _n -NR ⁵ R ^{5 '} , -C (= NR ⁵ ) NR ⁴ R ^5' ,

RR ⁵ °, RR ⁵ ° ^' each independently of one another H or A, A unbranched, branched or cyclic alkyl having 1-12 C atoms, in which 1-7 H atoms can also be replaced by F and / or chlorine, shark F, Cl, Br or I, n represent 0, 1, 2 or 3, and their pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all ratios.

8. Compounds according to claim 1 selected from the group (2R, 4R) -4-Hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - {[4- (2- {dimethylaminomethyl} phenyl) phenyl] - amide}, (2R, 4R) -4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2 - {[4- (2- {dimethylaminomethyl} phenyl ) -phenyl] -amide}, (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - {[2-fluoro-4- (2- {dimethylaminomethyl} phenyl) phenyl] amide}, (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2- {[2-fluoro-4- (2- {dimethylaminomethyl} phenyl) phenyl] amide}, (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chloro phenyl) amide] -2 - [(4- (2-dimethylaminomethylimidazol-1-yl) phenyl) amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1- [(4-ethynylphenyl) amide] -2 - [(4- (2-dimethylaminomethylimidazol-1-yl) phenyl) amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(2-fluoro-4- (2-dimethylaminomethyl-imidazol-1-yl) phenyl) amide], (2R, 4R ) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2 - [(2-fluoro-4- (2-dimethylaminomethylimidazol-1-yl) phenyl) amide], (2R, 4R ) -4-Hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(4- (Λ /, Λ / -dimethylamidino) phenyl) amide ], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2 - [(4 - (/ V, Λ / -dimethyl-amidino ) -phenyl) -amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) -amide] -2 - [(2-fluoro-4- (Λ /, A / -dimethyl-amidino) -phenyl) -amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] - 2 - [(2-fluoro-4- (Λ /, Λ / -dimethyl-amidino) -phenyl) -amide], (2R, 4R) -4-hydroxy-pyrrolidine-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2 - [(4- (1-methyl-4,5-dihydro-1 H-imidazol-2-yl) phenyl) amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-chlorophenyl) amide] -2- [ (2-fluoro-4- (1-methyl-4,5-dihydro-1H-imidazol-2-yl) phenyl) amide], (2R, 4R) -4-hydroxy-pyrrolidin-1, 2-dicarboxylic acid -1 - [(4-ethynylphenyl) amide] -2 - [(4- (1-methyl-4,5-dihydro-1 - imidazol-2-yl) phenyl) amide], (2R , 4R) -4-Hydroxy-pyrrolidin-1, 2-dicarboxylic acid 1 - [(4-ethynylphenyl) amide] -2 - [(2-fluoro-4- (1-methyl-4,5-dihydro -1H-imidazol-2-yl) - phenyl) -amide], and their pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all ratios.

9. A process for the preparation of compounds of formula I according to claims 1-8 and their pharmaceutically usable derivatives, solvates, salts and stereoisomers, characterized in that a) a compound of formula II

wherein R has the meaning given in claim 1, is reacted with a chloroformate derivative to give an intermediate carbamate derivative, which is then reacted with a compound of the formula III wherein

R ¹ , R ² , R ³ and R ^{4 have} the meaning given in claim 1,

is implemented

or

b) a compound of formula III

with a compound of formula IV

wherein

R has the meaning given in claim 1,

implements,

or

c) a compound of formula V wherein R ³ and R ^{4 have} the meaning given in claim 1, with a compound of formula VI

wherein L is Cl, Br, I or a free or reactive functional OH group and R, R ¹ and R ^{2 have} the meanings given in Claim 1, and / or a base or acid of the formula I in one of its salts transforms.

10. Compounds of formula I according to one or more of claims 1 to 9 as inhibitors of the coagulation factor Xa.

11. Compounds of formula I according to one or more of claims 1 to 9 as inhibitors of the coagulation factor Vlla.

12. Medicament containing at least one compound of the formula I according to one or more of claims 1 to 9 and / or its pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all ratios, and, if appropriate, carriers and / or auxiliaries.

13. Medicament containing at least one compound of formula I according to one or more of claims 1 to 9 and / or its pharmaceutically usable derivatives, solvates, salts and stereoisomers, including their mixtures in all ratios, and at least one further active pharmaceutical ingredient.

14. Use of compounds according to one or more of claims 1 to 9 and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication , Migraines, tinnitus, tumors, tumor diseases and / or tumor metastases.

15. Set (kit) consisting of separate packs of (a) an effective amount of a compound of formula I according to one or more of claims 1 to 9 and / or its pharmaceutically usable derivatives, solvates, salts and stereoisomers, including mixtures thereof in all proportions, and (b) an effective amount of another drug ingredient.

16. Use of compounds of formula I according to one or more of claims 1 to 9 and / or their pharmaceutical usable derivatives, solvates, salts and stereoisomers, including their mixtures in all ratios, for the manufacture of a medicament for the treatment of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy,

Angina pectoris, restenosis after angioplasty, intermittent claudication, migraine, tinnitus, tumors, tumor diseases and / or tumor metastases, in combination with at least one other active pharmaceutical ingredient.